Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on April 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

BridgeBio Pharma Stock Up 0.8%

BBIO stock traded up $0.54 during trading on Tuesday, hitting $65.22. The company had a trading volume of 1,000,218 shares, compared to its average volume of 2,763,645. The firm has a market capitalization of $12.77 billion, a P/E ratio of -17.39 and a beta of 1.02. BridgeBio Pharma, Inc. has a 52-week low of $31.77 and a 52-week high of $84.94. The company has a 50 day simple moving average of $71.23 and a 200-day simple moving average of $71.47.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.52 million for the quarter, compared to the consensus estimate of $178.07 million. During the same quarter last year, the firm posted ($0.88) EPS. BridgeBio Pharma’s quarterly revenue was up 66.8% compared to the same quarter last year. Sell-side analysts forecast that BridgeBio Pharma, Inc. will post -2.05 earnings per share for the current year.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: BridgeBio submitted an NDA to the FDA for encaleret in ADH1, a major regulatory milestone that could move the drug closer to approval and future revenue generation. The company also highlighted positive Phase 3 CALIBRATE results showing rapid, durable clinical benefit. Article: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
• Positive Sentiment: HC Wainwright raised its earnings estimates for BridgeBio Pharma and kept a Buy rating with a $110 price target, reinforcing a constructive view on the company’s long-term outlook. Article: HC Wainwright estimate and target price updates for BBIO
• Positive Sentiment: BridgeBio’s acoramidis data continues to show disease-modifying effects in ATTR-CM, which may support confidence in the commercial potential of its lead cardiovascular asset. Article: Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM
• Positive Sentiment: The company announced a $500 million stock repurchase program, a shareholder-friendly move that can help support the share price and signal confidence in future cash flow. Article: BridgeBio Pharma Announces $500 Million Stock Repurchase Program
• Neutral Sentiment: Analysts have been updating estimates after BridgeBio’s first-quarter results, reflecting continued attention on the company’s pipeline and earnings outlook, but without a clear immediate directional signal. Article: Analysts Are Updating Their BridgeBio Pharma, Inc. Estimates After Its First-Quarter Results
• Negative Sentiment: CEO Neil Kumar sold 40,000 shares under a pre-arranged 10b5-1 plan, which can still create mild pressure on investor sentiment despite the routine nature of the trade. Article: SEC Form 4 insider sale by Neil Kumar

Insider Buying and Selling

In other news, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $71.58, for a total transaction of $143,160.00. Following the completion of the sale, the chief accounting officer owned 134,115 shares of the company’s stock, valued at $9,599,951.70. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 64,921 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the sale, the director directly owned 18,589 shares of the company’s stock, valued at $1,205,868.43. The trade was a 77.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 239,084 shares of company stock worth $16,615,979 in the last 90 days. 14.23% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on BBIO. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Mizuho restated an “outperform” rating and issued a $106.00 price target on shares of BridgeBio Pharma in a report on Tuesday, April 28th. Morgan Stanley lifted their target price on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wells Fargo & Company lifted their target price on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Finally, Truist Financial lifted their target price on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Twenty-four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.19.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp purchased a new stake in BridgeBio Pharma in the 1st quarter worth $35,000. First Trust Advisors LP increased its holdings in BridgeBio Pharma by 200.4% in the 2nd quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock worth $11,386,000 after acquiring an additional 175,918 shares in the last quarter. Baird Financial Group Inc. increased its holdings in BridgeBio Pharma by 1.8% in the 2nd quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock worth $1,816,000 after acquiring an additional 731 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in BridgeBio Pharma in the 2nd quarter worth $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in BridgeBio Pharma by 2.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after acquiring an additional 2,206 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.